Effect of different polymers on avanafil-β-cyclodextrin inclusion complex: in vitro and in vivo evaluation

被引:10
作者
Soliman, Kareem AbuBakr [1 ]
Ibrahim, Howida Kamal [1 ]
Ghorab, Mahmoud Mohammed [1 ]
机构
[1] Cairo Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Kasr El Aini St,POB 11562, Cairo, Egypt
关键词
Polyethylene glycol; Polyvinyl pyrrolidone; Crystallinity; Stability; Bioavailability; POLYETHYLENE-GLYCOL; ERECTILE DYSFUNCTION; SOLID DISPERSIONS; THERMAL-ANALYSIS; EFFICIENCY; SOLUBILITY; ABSORPTION; BEHAVIOR; ENHANCE; CD;
D O I
10.1016/j.ijpharm.2016.08.044
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this study, we examined the effect of different polymers on the chemical, physical and pharmacokinetic properties of avanafil-beta-cyclodextrin (beta-CD) inclusion complex. Equimolar mixtures of drug and beta-CD were used to prepare 25 ternary drug-beta-CD-polymer inclusion complexes using five different polymers, polyethylene glycol (PEG 4000), polyvinyl pyrrolidone (PVP K-30), chitosan, hydroxypropylmethyl cellulose, and hydroxyethyl cellulose, each in five different concentrations, 1, 3, 5, 7, and 10% (w/w). The addition of 10% (w/w) PEG 4000 resulted in a significant decrease of drug solubility, where the infrared spectra and differential scanning thermograms revealed an interaction between PEG 4000 and avanafil which hindered drug inclusion. In contrast, addition of 7% (w/w) PVP K-30 facilitated drug inclusion as concluded from differential scanning thermograms, X-ray diffraction patterns and scanning electron micrographs. This resulted in a subsequent improvement in drug solubility and in vitro dissolution. This formula was chemically and physically stable for 6 months under accelerated storage conditions. The formula had a relative bioavailability of 125.56% in rabbits as compared to conventional commercially available avanafil tablets (Spedra (R)). (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:168 / 177
页数:10
相关论文
共 38 条
[1]   Future prospects in the treatment of erectile dysfunction: focus on avanafil [J].
Alwaal, Amjad ;
Al-Mannie, Raed ;
Carrier, Serge .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2011, 5 :435-443
[2]   Formulation and biological evaluation of glimepiride-cyclodextrin-polymer systems [J].
Ammar, HO ;
Salama, HA ;
Ghorab, M ;
Mahmoud, AA .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 309 (1-2) :129-138
[3]   An evaluation of fit factors and dissolution efficiency for the comparison of in vitro dissolution profiles [J].
Anderson, NH ;
Bauer, M ;
Boussac, N ;
Khan-Malek, R ;
Munden, P ;
Sardaro, M .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1998, 17 (4-5) :811-822
[4]  
[Anonymous], 2009, Stability testing of active pharmaceutical ingredients and finished pharmaceutical products
[5]  
[Anonymous], 2005, GUID IND EST MAX SAF
[6]   Binary and ternary inclusion complexes of finasteride in HPβCD and polymers: Preparation and characterization [J].
Asbahr, Ana Carolina C. ;
Franco, Luzia ;
Barison, Andersson ;
Silva, Caroline W. P. ;
Ferraz, Humberto G. ;
Rodrigues, Leticia N. C. .
BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (07) :2718-2723
[7]   Avanafil for treatment of erectile dysfunction: review of its potential [J].
Burke, Ryan M. ;
Evans, Jeffery D. .
VASCULAR HEALTH AND RISK MANAGEMENT, 2012, 8 :517-523
[8]   Cyclodextrins in drug delivery: An updated review [J].
Challa, R ;
Ahuja, A ;
Ali, J ;
Khar, RK .
AAPS PHARMSCITECH, 2005, 6 (02)
[9]  
ENDRENYI L, 1991, INT J CLIN PHARM TH, V29, P394
[10]  
European Medicine Agency, 2013, European Public Assessment Reports (EPAR)